Literature DB >> 24953416

Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre.

Z Song1, Y Zhang2.   

Abstract

AIMS: Thymic carcinoma is a rare and invasive mediastinal tumor, with poor prognosis. The optimal treatment for thymic carcinoma is not well defined currently.
METHODS: A single-institution retrospective study of patients operated for thymic carcinoma between 1996 and 2011 was conducted. Survival curves were plotted using the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analysis.
RESULTS: Seventy-six patients underwent surgery for thymic carcinoma. Masaoka stage was I in 11 patients, II in 20, III in 32, IVa in 13. A complete resection (R0) was achieved in 59 patients. Adjuvant radio/chemotherapy was offered to 58 patients. The 5-year disease-free survival rate and overall survival rate for all the patients were 59.7% and 66.2%, respectively. Patients with incomplete resection had a significantly worse disease-free survival and overall survival as compared to complete resection with univariate analyses (both p < 0.001). Multivariate analysis revealed that complete resection and Masaoka stage were statistically associated with disease-free survival and overall survival (p = 0.005 and 0.013 with complete resection; p = 0.006 and 0.009 with Masaoka stage).
CONCLUSIONS: Our result indicated that complete resection and Masaoka stage could impact the disease-free survival and overall survival of patients with thymic carcinoma after surgical resection.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Masaoka staging system; Prognosis; Surgery; Thymic carcinoma

Mesh:

Year:  2014        PMID: 24953416     DOI: 10.1016/j.ejso.2014.05.011

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Metabolomic and Transcriptomic Profiling Identified Significant Genes in Thymic Epithelial Tumor.

Authors:  Enyu Tang; Yang Zhou; Siyang Liu; Zhiming Zhang; Rixin Zhang; Dejing Huang; Tong Gao; Tianze Zhang; Guangquan Xu
Journal:  Metabolites       Date:  2022-06-20

2.  Treatment and survival analyses of completely resected thymic carcinoma patients.

Authors:  Yanjiao Mao; Shixiu Wu
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

3.  Adjuvant Therapy for Thymic Carcinoma--A Decade of Experience in a Taiwan National Teaching Hospital.

Authors:  Yen-Han Tseng; Yi-Hsuan Lin; Yen-Chiang Tseng; Yu-Chin Lee; Yu-Chung Wu; Wen-Hu Hsu; Sang-Hue Yen; Jacqueline Whang-Peng; Yuh-Min Chen
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

4.  Surgery Resection of a Massive Thymic Carcinoma during Urgent Coronary Artery Bypass Grafting.

Authors:  Selman Dumani; Ermal Likaj; Aferdita Veseli; Stavri Llazo; Leart Berdica; Ali Refatllari
Journal:  Open Access Maced J Med Sci       Date:  2018-06-16

5.  Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.

Authors:  Zhengbo Song; Guangyuan Lou; Yina Wang; Zhiping Yang; Wenxian Wang; Yongling Ji; Shiqing Chen; Chunwei Xu; Xiao Hu; Yiping Zhang
Journal:  BMC Med       Date:  2022-05-10       Impact factor: 8.775

6.  Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level.

Authors:  Xinyu Qian; Zhengbo Song
Journal:  Onco Targets Ther       Date:  2016-07-22       Impact factor: 4.147

7.  A single-center experience: management of patients with thymic epithelial tumors.

Authors:  Marius Kemper; Mona Moradzadeh; Eugen Bellon; Ahmad S Bahar; Rainer Grotelüschen; Matthias Reeh; Jakob R Izbicki; Kai Bachmann
Journal:  World J Surg Oncol       Date:  2020-08-13       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.